BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15209739)

  • 1. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen.
    Yang Q; Cleary KR; Yao JC; Swisher SG; Roth JA; Lynch PM; Komaki R; Ajani JA; Rashid A; Hamilton SR; Wu TT
    Dis Esophagus; 2004; 17(1):38-43. PubMed ID: 15209739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus.
    Rohatgi PR; Swisher SG; Correa AM; Wu TT; Liao Z; Komaki R; Walsh G; Vaporciyan A; Lynch PM; Rice DC; Roth JA; Ajani JA
    Cancer; 2005 Oct; 104(7):1349-55. PubMed ID: 16130133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.
    Brücher BL; Becker K; Lordick F; Fink U; Sarbia M; Stein H; Busch R; Zimmermann F; Molls M; Höfler H; Siewert JR
    Cancer; 2006 May; 106(10):2119-27. PubMed ID: 16607651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
    Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer.
    Sarkaria IS; Rizk NP; Bains MS; Tang LH; Ilson DH; Minsky BI; Rusch VW
    Ann Surg; 2009 May; 249(5):764-7. PubMed ID: 19387328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
    Chirieac LR; Swisher SG; Correa AM; Ajani JA; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Clin Cancer Res; 2005 Mar; 11(6):2229-36. PubMed ID: 15788671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer.
    Luu TD; Gaur P; Force SD; Staley CA; Mansour KA; Miller JI; Miller DL
    Ann Thorac Surg; 2008 Apr; 85(4):1217-23; discussion 1223-4. PubMed ID: 18355499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation.
    Wang KL; Yang Q; Cleary KR; Swisher SG; Correa AM; Komaki R; Ajani JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Oct; 107(7):1467-74. PubMed ID: 16955509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system.
    Gertler R; Stein HJ; Langer R; Nettelmann M; Schuster T; Hoefler H; Siewert JR; Feith M
    Ann Surg; 2011 Apr; 253(4):689-98. PubMed ID: 21475008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation.
    Chirieac LR; Swisher SG; Ajani JA; Komaki RR; Correa AM; Morris JS; Roth JA; Rashid A; Hamilton SR; Wu TT
    Cancer; 2005 Apr; 103(7):1347-55. PubMed ID: 15719440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.
    Wu TT; Chirieac LR; Abraham SC; Krasinskas AM; Wang H; Rashid A; Correa AM; Hofstetter WL; Ajani JA; Swisher SG
    Am J Surg Pathol; 2007 Jan; 31(1):58-64. PubMed ID: 17197919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
    Kulke MH; Odze RD; Mueller JD; Wang H; Redston M; Bertagnolli MM
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1579-86. PubMed ID: 15173710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of postchemoradiation endoscopic brush cytology and biopsy in predicting residual esophageal adenocarcinoma.
    Peng HQ; Halsey K; Sun CC; Manucha V; Nugent S; Rodgers WH; Suntharalingam M; Greenwald BD
    Cancer; 2009 Dec; 117(6):463-72. PubMed ID: 19806643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic importance of pathologically involved celiac node metastases in node-positive patients with carcinoma of the distal esophagus or gastroesophageal junction: a surgical series from the Mayo Clinic.
    Schomas DA; Quevedo JF; Donahue JM; Nichols FC; Romero Y; Miller RC
    Dis Esophagus; 2010 Apr; 23(3):232-9. PubMed ID: 19515184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
    Barthel JS; Kucera ST; Lin JL; Hoffe SE; Strosberg JR; Ahmed I; Dilling TJ; Stevens CW
    Gastrointest Endosc; 2010 Feb; 71(2):235-40. PubMed ID: 20003971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Positive Margins on Survival in Patients Undergoing Esophagogastrectomy for Esophageal Cancer.
    Javidfar J; Speicher PJ; Hartwig MG; D'Amico TA; Berry MF
    Ann Thorac Surg; 2016 Mar; 101(3):1060-7. PubMed ID: 26576752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.